T1	Participants 75 113	early-stage non-small-cell lung cancer
T2	Participants 282 337	resectable StageI-II non-small-cell lung cancer (NSCLC)
T3	Participants 352 364	multicenter,
T4	Participants 847 868	total of 528 patients
